{
    "Trade/Device Name(s)": [
        "Tina-quant HbA1c Gen. 3",
        "HbA1c Gen. 3"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K102914",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072714"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP"
    ],
    "Summary Letter Date": "December 20, 2010",
    "Summary Letter Received Date": "December 21, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole Blood",
        "Hemolysate"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "Na-heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Sodium fluoride/Na-EDTA tube",
        "Sodium fluoride/potassium oxalate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "COBAS INTEGRA 800 analyzer",
        "Integra 400",
        "Integra 400 plus"
    ],
    "Method(s)/Technology(ies)": [
        "Turbidimetric inhibition immunoassay (TINIA)",
        "Bichromatic photometric determination"
    ],
    "Methodologies": [
        "Immunoassay",
        "Photometry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent System"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Tina-quant HbA1c Gen. 3 assay for the quantitative measurement of hemoglobin A1c in whole blood and hemolysate using turbidimetric inhibition immunoassay on Roche clinical chemistry analyzers",
    "Indications for Use Summary": "Quantitative determination of mmol/mol hemoglobin A1c (IFCC) and percent hemoglobin A1c (DCCT/NGSP) in whole blood and hemolysate, for monitoring long-term blood glucose control in individuals with diabetes mellitus",
    "fda_folder": "Hematology"
}